Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 9, 2016PLoS ONEOpen Access

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

View Full Paper
Ask AI
Bookmark
Share

Authors

MSMark SelbyJEJohn EngelhardtRJRobert J. Johnston

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Selby et al. (2016) studied this question.

synapsesocial.com/papers/6a8082ae01fdebfcdaeea38fhttps://doi.org/10.1371/journal.pone.0161779
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Confusing signals: Recent progress in CTLA-4 biology2015 · 345 citations
  2. 2Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques2003 · 132 citations
  3. 3Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.2016 · 140 citations
  4. 4CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms2005 · 1,953 citations
  5. 5<i>In Vitro</i> Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and <i>In Vivo</i> Toxicology in Non-Human Primates2014 · 606 citations